DiaMedica Therapeutics Inc.
DMAC · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 12.24 | 0.00 | -0.37 | -0.46 |
| FCF Yield | -4.54% | -4.41% | -2.77% | -2.50% |
| EV / EBITDA | -21.29 | -19.69 | -27.33 | -25.51 |
| Quality | ||||
| ROIC | -29.18% | -23.78% | -20.53% | -14.23% |
| Gross Margin | 0.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 0.77 | 0.99 | 0.93 | 0.81 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -6.19% | -11.18% | -43.80% | 0.89% |
| Safety | ||||
| Net Debt / EBITDA | 0.50 | 0.28 | 0.32 | 0.55 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -37,830.00 | -12,330.00 | 1.54 | -15.31 |